Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) SHH

45.24

+0.19(+0.42%)

Updated at October 20 09:53AM

Currency In CNY

Mabwell (Shanghai) Bioscience Co., Ltd.

Address

Building 2 Room 105, No. 230 Cailun RoadChina (Shanghai) Pilot Free Trade Zone Shanghai, 201210China

Shanghai, 201210

China

Phone

86 21 5833 2260

Sector

Healthcare

Industry

Biotechnology

Employees

1416

First IPO Date

January 18, 2022

Key Executives

NameTitlePayYear Born
Dr. Datao LiuChairman, Chief Executive Officer & GM01972
Dr. Xin DuChief Scientific Officer & President of Maiwei (US)01972
Ms. Xi ChenDeputy General Manager01980
Mr. Huiguo HuDeputy GM, Secretary of the Board of Directors & Director01977
Mr. Weiyi DongDeputy General Manager01957
Dr. Yinhan GuoChief Research & Development Officer01971
Mr. Han LiDeputy General Manager01971
Mr. Jinchao ZhangDeputy General Manager01972
Mr. Hua NiDeputy General Manager01970
Mr. Shu Hai WangDeputy General Manager01974

Description

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes 9MW2821 and 6MW3211, which are in phase II of clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; 9MW0321; and 8MW0511, which is in phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; metabolic products comprising MAILISHU and 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is based in Shanghai, China.